S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
NASDAQ:CBAY

CymaBay Therapeutics Stock Forecast, Price & News

$3.80
-0.09 (-2.31 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.79
$3.90
50-Day Range
$3.47
$4.31
52-Week Range
$3.39
$9.06
Volume170,365 shs
Average Volume812,741 shs
Market Capitalization$262.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
30 days | 90 days | 365 days | Advanced Chart
Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


CymaBay Therapeutics logo

About CymaBay Therapeutics

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products pipeline include Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

540th out of 1,351 stocks

Pharmaceutical Preparations Industry

264th out of 664 stocks

Analyst Opinion: 3.6Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

Is CymaBay Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CymaBay Therapeutics stock.
View analyst ratings for CymaBay Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CymaBay Therapeutics?

Wall Street analysts have given CymaBay Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CymaBay Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for CymaBay Therapeutics
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its quarterly earnings results on Thursday, August, 12th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.07.
View CymaBay Therapeutics' earnings history
.

How has CymaBay Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CBAY stock has increased by 146.8% and is now trading at $3.80.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CBAY?

8 Wall Street analysts have issued 1 year price objectives for CymaBay Therapeutics' stock. Their forecasts range from $7.00 to $12.00. On average, they expect CymaBay Therapeutics' share price to reach $10.13 in the next year. This suggests a possible upside of 166.4% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the following people:
  • Sujal Shah, President, Chief Executive Officer & Director
  • Daniel Menold, Vice President-Finance
  • Charles A. McWherter, Chief Scientific Officer & Senior Vice President
  • Dennis D. Kim, Chief Medical Officer
  • Paul T. Quinlan, Secretary & Chief Compliance Officer

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.87%), Commodore Capital LP (5.12%), Vanguard Group Inc. (4.82%), State Street Corp (1.97%), Dimensional Fund Advisors LP (1.68%) and Geode Capital Management LLC (1.66%).
View institutional ownership trends for CymaBay Therapeutics
.

Which institutional investors are selling CymaBay Therapeutics stock?

CBAY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wells Fargo & Company MN, Dimensional Fund Advisors LP, State of Wisconsin Investment Board, Deutsche Bank AG, Renaissance Technologies LLC, and Parametric Portfolio Associates LLC.
View insider buying and selling activity for CymaBay Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was bought by a variety of institutional investors in the last quarter, including Commodore Capital LP, Kestra Private Wealth Services LLC, Morgan Stanley, Morgan Stanley, Commonwealth Equity Services LLC, Rockefeller Capital Management L.P., Price T Rowe Associates Inc. MD, and State Street Corp.
View insider buying and selling activity for CymaBay Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $3.80.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics has a market capitalization of $262.19 million. The biopharmaceutical company earns $-50,990,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does CymaBay Therapeutics have?

CymaBay Therapeutics employs 44 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is www.cymabay.com.

Where are CymaBay Therapeutics' headquarters?

CymaBay Therapeutics is headquartered at 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at (510) 293-8800 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.